- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00243464
Efficacy of Calcipotriol Plus Betamethasone Gel Versus Calcipotriol Scalp Solution in Scalp Psoriasis
Calcipotriol Plus Betamethasone Dipropionate Gel Compared to DAIVONEX/DOVONEX Scalp Solution in Patients With Scalp Psoriasis
The purpose of this study is to evaluate whether once daily treatment for up to 8 weeks of calcipotriol plus betamethasone dipropionate gel is more effective than twice daily treatment of calcipotriol scalp solution in patients with scalp psoriasis. The primary outcome is patients with clear or minimal disease after 8 weeks treatment.
Further the occurrence of relapse and rebound after end of treatment in patients with clear or minimal disease will be investigated.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Leuven, Belgium, 3000
- Universitair Ziekenhuis Sint Raphaël, Dienst Dermatologie
-
-
-
-
Ontario
-
Windsor, Ontario, Canada, N8W5L7
- Windsor Clinical Research Inc.
-
-
-
-
-
Aarhus, Denmark, 8000
- Department of Dermatology, Marselisborg Centres
-
-
-
-
-
Nice, France, 06202
- Hôpital de L'Archet, Service de Dermatologie
-
-
-
-
-
Göteborg, Sweden, 41135
- Läkarhuset
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Main Inclusion Criteria:
- Scalp psoriasis amenable to topical treatment
- Psoriasis vulgaris on trunk and/or limbs
- Extent of scalp psoriasis involving more than 10% of the total scalp area
- Disease severity on the scalp graded as moderate or worse by the investigator
- Consenting out-patients of 18 years or above
Main Exclusion Criteria:
- PUVA or Grenz ray therapy within 4 weeks prior to randomisation
- UVB therapy within 2 weeks prior to randomisation
- Systemic treatment with biological therapies, with a possible effect on scalp psoriasis within 6 months prior to randomisation
- Systemic treatment with all other therapies than biologicals, with a possible effect on scalp psoriasis (e.g., corticosteroids, vitamin D analogues, retinoids, immunosuppressants) within 4 weeks prior to randomisation
- Any topical treatment of the scalp (except for non steroid medicated shampoos and emollients) within 2 weeks prior to randomisation
- Topical treatment of the face, trunk and/or limbs with very potent WHO group IV corticosteroids within 2 weeks prior to randomisation
- Current diagnosis of erythrodermic, exfoliative or pustular psoriasis
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Overall disease severity according to investigator's assessment at week 8
|
Secondary Outcome Measures
Outcome Measure |
---|
Total sign score at week 8
|
Overall disease severity according to patients at week 8
|
Score for redness, thickness and scaliness at week 8
|
Overall disease severity according to the investigator's assessment at week 2 and 4
|
Relapse and rebound during the study
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Knud Kragballe, MD, Department of Dermatology, Marselisborg Centres
Study record dates
Study Major Dates
Study Start
Study Completion
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Skin Diseases
- Skin Diseases, Papulosquamous
- Psoriasis
- Physiological Effects of Drugs
- Anti-Inflammatory Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Dermatologic Agents
- Anti-Asthmatic Agents
- Respiratory System Agents
- Betamethasone
- Betamethasone Valerate
- Betamethasone-17,21-dipropionate
- Betamethasone benzoate
- Calcipotriene
- Betamethasone sodium phosphate
Other Study ID Numbers
- MBL 0503 INT
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Psoriasis of Scalp
-
LEO PharmaCompletedPsoriasis of ScalpCanada, Denmark, France, Germany, United Kingdom
-
LEO PharmaCompletedPsoriasis of ScalpCanada, Belgium, Finland, France, Germany, Netherlands, United Kingdom
-
University of California, San FranciscoJanssen Scientific Affairs, LLCRecruiting
-
LEO PharmaCompletedPsoriasis of ScalpCanada, Denmark, France, Norway, Portugal, Spain, Sweden, United Kingdom
-
Clin4allRecruitingPsoriasis of Scalp | Psoriasis Nail | Psoriasis Palmaris | Psoriasis Genital | Psoriasis PlantarisFrance
-
University of ZurichUnknownPsoriasis Vulgaris | Psoriasis of ScalpSwitzerland
-
ProgenaBiomeRecruitingPsoriasis | Psoriasis Vulgaris | Psoriasis of Scalp | Psoriatic Plaque | Psoriasis Universalis | Psoriasis Face | Psoriasis Nail | Psoriasis Diffusa | Psoriasis Punctata | Psoriasis Palmaris | Psoriasis Circinata | Psoriasis Annularis | Psoriasis Genital | Psoriasis GeographicaUnited States
-
Janssen Research & Development, LLCActive, not recruitingPlaque Psoriasis | Scalp PsoriasisUnited States, Canada
-
Paul Steven Yamauchi, MD, PhDJanssen Services, LLCUnknownA Study to Evaluate the Effectiveness of STELARA ™ (USTEKINUMAB) in the Treatment of Scalp PsoriasisPlaque Psoriasis | Scalp PsoriasisUnited States
-
Centre of Evidence of the French Society of DermatologyRecruitingPsoriasis | Psoriasis Vulgaris | Psoriasis of Scalp | Psoriatic Plaque | Psoriasis Universalis | Psoriasis Palmaris | Psoriatic Erythroderma | Psoriatic Nail | Psoriasis Guttate | Psoriasis Inverse | Psoriasis PustularFrance
Clinical Trials on Calcipotriol plus betamethasone dipropionate (LEO80185 gel)
-
LEO PharmaCompletedPsoriasis of ScalpCanada, Denmark, France, Norway, Portugal, Spain, Sweden, United Kingdom
-
LEO PharmaCompletedPsoriasis of ScalpCanada, Belgium, Finland, France, Germany, Netherlands, United Kingdom
-
LEO PharmaCompletedPsoriasis VulgarisIreland, Germany, United Kingdom, Canada, Sweden
-
LEO PharmaCompletedPsoriasis of ScalpCanada, Denmark, France, Germany, United Kingdom
-
Jooheung LeeCompletedPsoriasis VulgarisKorea, Republic of
-
LEO PharmaCompleted
-
LEO PharmaCompleted
-
LEO PharmaCompleted
-
LEO PharmaCompletedPsoriasis VulgarisRussian Federation
-
Garlapati KomaliUnknown